Combination therapyInvestigationalInvestigational
Pembrolizumab + ipilimumab
How it works
Combination of pembrolizumab, which blocks PD-1, and ipilimumab, which blocks CTLA-4, allowing the immune system to attack cancer cells.
Cancer types
Melanoma— All patients
Efficacy
In clinical trials, around 58% of patients achieved an objective response, with a median overall survival of approximately 16.9 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.